Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 47 clinical trials
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321) (BRUIN-MCL-321)

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation …

measurable disease
cancer
btk inhibitor
ibrutinib
acalabrutinib
  • 27 views
  • 16 Sep, 2022
  • 160 locations
An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients

This is an open-label study, to evaluate the efficacy and safety of a BTK inhibitor zanubrutinib in participants with NMOSDs.

azathioprine
prednisone
immunosuppressive agents
  • 0 views
  • 03 Jun, 2022
  • 1 location
Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

This is a first-in-human (FIH), multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK

  • 0 views
  • 19 Jun, 2022
  • 1 location
R-MTX-zanbrutinib in Secondary CNS Lymphoma

SCNSL, and new therapeutic strategies are urgently needed. Zanubrutinib is a new second-generation BTK inhibitor, which has showed good efficacy and safety in a variety of B-NHL. Zanubrutinib has showed

  • 0 views
  • 17 Jun, 2022
  • 1 location
STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR)

The irreversible Bruton's Tyrosine Kinase (BTK) inhibitor acalabrutinib (ACA) has potent clinical activity as a single agent in patients with treatment naive and Relapsed/Refractory Chronic

  • 0 views
  • 10 Mar, 2022
  • 13 locations
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (BRUIN CLL-321)

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is

chronic lymphocytic leukemia
btk inhibitor
idelalisib
rituximab
bendamustine
  • 5 views
  • 16 Sep, 2022
  • 202 locations
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (ELM-2)

) grade 1-3a *1,2 In patients with diffuse large B-cell lymphoma (DLBCL) *1,2 In patients with mantle cell lymphoma (MCL) that has relapsed after or is refractory to a BTK inhibitor

b-cell lymphoma
diffuse large b-cell lymphoma
mantle cell lymphoma
tositumomab
large b-cell lymphoma
  • 69 views
  • 20 Sep, 2022
  • 129 locations
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

This multicenter, prospective, open-label, randomized, superiority phase 3 study is designed to demonstrate that treatment with a triple combination of acalabrutinib, obinutuzumab and venetoclax (GAVe) prolong the progression-free survival (PFS) as compared to treatment with the combination of obinutuzumab and venetoclax (GVe) in pa-tients with high risk CLL (defined as …

gilbert's syndrome
TP53
venetoclax
obinutuzumab
acalabrutinib
  • 0 views
  • 27 May, 2022
  • 2 locations
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma

concurrent BTK inhibitor in patients with relapsed or refractory B cell lymphoma

mantle cell lymphoma
lymphocytic leukemia
lymphoma
fludarabine
leukemia
  • 0 views
  • 28 Oct, 2021
  • 1 location
A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma

To observe the efficacy and safety of a new generation of BTK inhibitor Orelabrutinib combined with PD-1 and fotemustine in the treatment of patients with primary central nervous system lymphoma

  • 0 views
  • 20 Jun, 2022
  • 1 location